These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36813747)

  • 1. Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
    He J; Ma P; Zhao D; Shi X; Guo R; Gao W; Shu Y
    Cancer; 2023 May; 129(10):1513-1522. PubMed ID: 36813747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
    Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
    J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
    Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
    Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.
    Shi Y; Wu S; Wang K; Cang S; Yao W; Fan Y; Wu L; Huang M; Li X; Pan Y; Yang Z; Zhu B; Chen G; Shi J; Sun M; Fang J; Wang L; Chen Z; Liu C; Li J; Liu J; Sun S; Zhao Y; Guo Y; Meng Z; Liu Z; Han Z; Lu H; Ma R; Hu S; Zhao G; Liu Z; Xie C; Zhong D; Zhao H; Yu H; Zhang L; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Shu Y; Chen Z; Guo Z; Greco M; Wang T; Shen H
    J Thorac Oncol; 2022 Nov; 17(11):1306-1317. PubMed ID: 36049654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.
    Kim DW; Lee DH; Han JY; Lee J; Cho BC; Kang JH; Lee KH; Cho EK; Kim JS; Min YJ; Cho JY; An HJ; Kim HG; Lee KH; Kim BS; Jang IJ; Yoon S; Han O; Noh YS; Hong KY; Park K
    Lung Cancer; 2019 Sep; 135():66-72. PubMed ID: 31447004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
    Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
    Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics, and efficacy of BPI-15086 in patients with EGFR T790M-mutated advanced non-small-cell lung cancer: results from a phase I, single-arm, multicenter study.
    Xing P; Zheng X; Wang Y; Chu T; Wang S; Jiang J; Qian J; Han X; Ding L; Wang Y; Cui L; Li H; Li L; Chen X; Han B; Hu P; Shi Y
    ESMO Open; 2022 Jun; 7(3):100473. PubMed ID: 35526510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.
    Lu S; Zhang Y; Zhang G; Zhou J; Cang S; Cheng Y; Wu G; Cao P; Lv D; Jian H; Chen C; Jin X; Tian P; Wang K; Jiang G; Chen G; Chen Q; Zhao H; Ding C; Guo R; Sun G; Wang B; Jiang L; Liu Z; Fang J; Yang J; Zhuang W; Liu Y; Zhang J; Pan Y; Chen J; Yu Q; Zhao M; Cui J; Li D; Yi T; Yu Z; Yang Y; Zhang Y; Zhi X; Huang Y; Wu R; Chen L; Zang A; Cao L; Li Q; Li X; Song Y; Wang D; Zhang S; Ding L; Zhang L; Yuan X; Yao L; Shen Z
    J Thorac Oncol; 2022 Oct; 17(10):1192-1204. PubMed ID: 35724798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
    Yang JC; Camidge DR; Yang CT; Zhou J; Guo R; Chiu CH; Chang GC; Shiah HS; Chen Y; Wang CC; Berz D; Su WC; Yang N; Wang Z; Fang J; Chen J; Nikolinakos P; Lu Y; Pan H; Maniam A; Bazhenova L; Shirai K; Jahanzeb M; Willis M; Masood N; Chowhan N; Hsia TC; Jian H; Lu S
    J Thorac Oncol; 2020 Dec; 15(12):1907-1918. PubMed ID: 32916310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
    Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
    Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
    Xiong A; Ren S; Liu H; Miao L; Wang L; Chen J; Li W; Li R; Wang X; Lu Z; Wang D; Wu X; Liu Z; Xing L; Mao Y; Liu C; Zeng A; Niu H; Du Y; Sun Y; Pan Y; Hu Y; Zhang X; Chen X; Ma Z; Li N; Zhang J; Zhao M; Li X; Ye F; Li M; Yu G; Zhang X; Min J; Han D; Li J; Zhou C
    J Thorac Oncol; 2022 Oct; 17(10):1216-1226. PubMed ID: 35798241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
    Cho BC; Han JY; Kim SW; Lee KH; Cho EK; Lee YG; Kim DW; Kim JH; Lee GW; Lee JS; Shim BY; Kim JS; Chun SH; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Lee Y; Lee DH; Kang JA; Lee N; Kwon MJ; Espenschied C; Yablonovitch A; Ahn MJ
    J Thorac Oncol; 2022 Apr; 17(4):558-567. PubMed ID: 34958928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rociletinib in EGFR-mutated non-small-cell lung cancer.
    Sequist LV; Soria JC; Goldman JW; Wakelee HA; Gadgeel SM; Varga A; Papadimitrakopoulou V; Solomon BJ; Oxnard GR; Dziadziuszko R; Aisner DL; Doebele RC; Galasso C; Garon EB; Heist RS; Logan J; Neal JW; Mendenhall MA; Nichols S; Piotrowska Z; Wozniak AJ; Raponi M; Karlovich CA; Jaw-Tsai S; Isaacson J; Despain D; Matheny SL; Rolfe L; Allen AR; Camidge DR
    N Engl J Med; 2015 Apr; 372(18):1700-9. PubMed ID: 25923550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Trial of a Third Generation EGFR Mutant-Selective Inhibitor (D-0316) in Patients with Advanced Non-Small Cell Lung Cancer.
    Jian H; Wang K; Cheng Y; Ding L; Wang Y; Shi Z; Zhang L; Wang Y; Lu S
    Oncologist; 2022 Mar; 27(3):163-e213. PubMed ID: 35274722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.
    Kiura K; Yoh K; Katakami N; Nogami N; Kasahara K; Takahashi T; Okamoto I; Cantarini M; Hodge R; Uchida H
    Cancer Sci; 2018 Apr; 109(4):1177-1184. PubMed ID: 29363250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study.
    Shi Y; Zhao Y; Yang S; Zhou J; Zhang L; Chen G; Fang J; Zhu B; Li X; Shu Y; Shi J; Zheng R; Wang D; Yu H; Huang J; Zhuang Z; Wu G; Zhang L; Guo Z; Greco M; Li X; Zhang Y
    J Thorac Oncol; 2022 May; 17(5):708-717. PubMed ID: 35181498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Sa H; Shi Y; Ding C; Ma K
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7729-7742. PubMed ID: 37004599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
    Ma Y; Zheng X; Zhao H; Fang W; Zhang Y; Ge J; Wang L; Wang W; Jiang J; Chuai S; Zhang Z; Xu W; Xu X; Hu P; Zhang L
    J Thorac Oncol; 2018 Jul; 13(7):968-977. PubMed ID: 29626621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.